TapImmune Enters into Definitive Agreements to raise $8.5 Million

August 16th, 2016 | Posted In: Donna Blog, Front Page Feature, Research - Closer to the Finish, Research Updates

DONNA partner TapImmune, a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced August 11 its plans to enter into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million.